Ipamorelin cas 170851-70-4

Ipamorelin, also known as NNC-26-0161, is a a ghrelin mimetic. Ipamorelin counteracts glucocorticoid-induced decrease in bone formation of adult rats. Ipamorelin may ameliorate the symptoms in patients with POI. Ipamorelin accelerates gastric emptying in a rodent model of postoperative ileus through the stimulation of gastric contractility by activating a ghrelin receptor-mediated mechanism involving cholinergic excitatory neurons.

Related Prodcuts:

Dynorphin A (1-13); Deslorelin; Gonadorelin; Gonadorelin acetate; Sermorelin; Sermorelin Acetate; Etelcalcetide; DSIP; Lixisenatide; Angiotensin acetate; Epithalone; Buserelin; Cilengitide; Cilengitide trifluoroacetate; Tesamorelin; Selank; ACTH (1-39) Seractide

1: Semenistaya E, Zvereva I, Thomas A, Thevis M, Krotov G, Rodchenkov G. Determination of growth hormone releasing peptides metabolites in human urine after nasal administration of GHRP-1, GHRP-2, GHRP-6, Hexarelin, and Ipamorelin. Drug Test Anal. 2015 Oct;7(10):919-25. doi: 10.1002/dta.1787. PubMed PMID: 25869809.

2: Beck DE, Sweeney WB, McCarter MD; Ipamorelin 201 Study Group.. Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. Int J Colorectal Dis. 2014 Dec;29(12):1527-34. doi: 10.1007/s00384-014-2030-8. PubMed PMID: 25331030.